SCHEMBL3436247

SCHEMBL3436247

COC(=O)c1coc(COC(C)C)n1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
SLC6A3 Q01959 1/20 0.50
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
CACNA1G O43497 5/20 0.40
DAGLA Q9Y4D2 1/20 0.39
KCNH2 Q12809 2/20 0.39
HRH3 Q9Y5N1 3/20 0.38
P2RX3 P56373 1/20 0.37
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
GSK3B P49841 2/20 0.33
FBP1 P09467 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3436268 0.84 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL3436248 0.84 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL17562359 0.81 SLC6A2 (0.42) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL13141153 0.81 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL345210 0.80 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL2116168 0.79 DAGLA (0.43) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL16130104 0.79 DAGLA (0.43) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL29224178 0.78 CACNA1G (0.40) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL2172653 0.78 DAGLA (0.42) SLC6A2SLC6A4SLC6A3ALOX5APFEN1
SCHEMBL346006 0.78 CACNA1G (0.42) SLC6A2SLC6A4SLC6A3ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206707-B1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-07-23 EP disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 US disclosed
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 EP disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF TRPV1, FGFR3, GPR17 SLC6A2 1855/4885SLC6A4 1898/4885SLC6A3 1196/4885
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 SLC6A2 2876/4885SLC6A4 2509/4885SLC6A3 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.